Hair loss and Hedgehog inhibitors: A class effect?

British Journal of Dermatology

Volumn 173, Issue 1, 2015, Pages 262-264

  Ferguson, J S ^a   Hannam, S ^b   Toholka, R ^b   Chong, A H ^b   Magee, J ^c   Foley, P ^b  

^a QUEEN MARY S HOSPITAL   (United Kingdom)

^b SKIN AND CANCER FOUNDATION   (Australia)

^c Dorevitch Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; ELECTROLYTE; FERRITIN; FOLIC ACID; FORMALDEHYDE; MINOXIDIL; SONIC HEDGEHOG PROTEIN; SONIDEGIB; UREA; VISMODEGIB; ZINC; ANILIDE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BLOOD CELL COUNT; CELL SURFACE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FROZEN SECTION; HAIR LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LETTER; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; SCALP PRURITUS; THYROID FUNCTION TEST; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; CASE REPORT; MIDDLE AGED; SKIN NEOPLASMS;

ADULT; AGED; ALOPECIA; ANILIDES; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; FEMALE; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SKIN NEOPLASMS;

EID: 84948710040     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13619     Document Type: Letter

References (9)

1. Sekulic A, Migden MR, Oro AE, et al,. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-9.
2. Chang ALS, Solomon JA, Hainsworth JD, et al,. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2013; 70: 60-9.
3. Wang LC, Liu ZY, Gambardella L, et al,. Conditional disruption of Hedgehog signaling pathway defines its critical role in hair development and regeneration. J Invest Dermatol 2000; 114: 901-8.
4. Paladini RD, Saleh J, Qian C, et al,. Modulation of hair growth with small molecule agonists of the Hedgehog signaling pathway. J Invest Dermatol 2005; 125: 638-46.
5. Curis,. Curis provides update on Hedgehog agonist hair growth program. Available at: http://investors.curis.com/releasedetail.cfm?releaseid=633413 (last accessed 5 May 2015).
6. Hoffman La Roche,. STEVIE: a study of vismodegib in patients with locally advanced or metastatic basal cell carcinoma. Available at: http://clinicaltrials.gov/show/NCT01367665 (last accessed 5 May 2015).
7. Novartis. A phase II study of efficacy and safety in patients with locally advanced or metastatic basal cell carcinoma (BOLT). Available at: http://clinicaltrials.gov/show/NCT01327053 (last accessed 5 May 2015).
8. Sinclair R,. Chronic telogen effluvium: a study of 5 patients over 7 years. J Am Acad Dermatol 2005; 52 (2 Suppl. 1): 12-16.
9. Kanti V, Nuwayhid R, Lindner J, et al,. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study. Br J Dermatol 2014; 170: 643-50.